Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01513187
Other study ID # SOGUG-2010-01
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date July 11, 2011
Est. completion date February 22, 2019

Study information

Verified date March 2020
Source Spanish Oncology Genito-Urinary Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase I / II, open, prospective, multicenter single-arm, Clinical Trial in two stages: in the first stage it will determine the optimal dose of the combination of pazopanib and interferon alfa-A2 in the treatment of patients with advanced renal carcinoma and a second stage that will determine the efficacy of this combination measured in terms of response rate.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date February 22, 2019
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Signed informed consent 2. Age = 18 years. 3. Patients diagnosed histologically clear cell carcinoma of the kidney metastatic or unresectable locally advanced, previously untreated. However, in Phase I may include patients with primary tumors other than renal cell can benefit from these drugs and patients with renal cell carcinoma treated before. 4. Performance status (ECOG) 0-1. 5. Patients must have measurable disease by RECIST criteria V 1.1. Progression should be documented in the two months prior to study entry. 6. Patients may not have received prior treatment with anti-VEGF agents, mTOR inhibitors or cytokines. However, in Phase I may include patients who have received any previous treatment. 7. Paraffin tumor sample should be available and collection of serum from all subjects for biomarker analysis previously and / or during treatment with study medication. 8. Adequate Hematologic, liver and kidney functions. 9. Women of childbearing potential must be using an effective method of birth control (abstinence, any intrauterine device [IUD] published data showing that the expected minimum rate of failure is less than 1% per year, or any other method the published data show that the expected minimum rate of failure is less than 1% per year) before inclusion in the study and continue using it during the same six months after completion. Women of childbearing age should get a negative pregnancy test in urine or serum (minimum sensitivity 25 IU / L or equivalent units of beta fraction of human chorionic gonadotropin [ß-HCG]) during the seven days prior to the randomization. 10. Able to swallow oral compound. 11. Willingness and ability to attend scheduled visits, to follow the treatment schedule and to undergo clinical trials and other study procedures Exclusion Criteria: 1. History of prior malignancies diagnosed or treated over the past 5 years except basal cell skin cancer or prostate cancer incidentally detected previously treated. However, patients with a history of malignancy but free of the disease over the past 5 years, or patients with a history of nonmelanoma skin carcinoma-completely-resected or carcinoma in situ treated successfully can participate in the study . In Phase I, patients diagnosed with other previous or concomitant malignant diseases can be included. 2. Presence of metastases in the central nervous system (CNS) or leptomeningeal carcinomatosis, except for patients with previously treated CNS metastases, asymptomatic and have not needed corticosteroids or anticonvulsant drugs in the 3 months prior to administering the first dose of the drug under study. Only is required CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) if clinically indicated or if the individual has a history of CNS metastases. 3. Clinically significant gastrointestinal disorders may increase the risk of gastrointestinal bleeding including, but not limited to: Active peptic ulcer disease Known metastatic lesions with probable intraluminal bleeding Inflammatory bowel disease (ulcerative colitis, Crohn's disease) or other gastrointestinal disorders with increased risk of perforation History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days before the start of study treatment. 4. Clinically significant gastrointestinal abnormalities may affect the absorption of the investigational product such as but not limited to: Malabsorption syndrome Major resection of the stomach or small intestine Grade 3 diarrhea 5. Patients with active infection or other disease or serious medical condition. 6. Prolongation of the corrected QT wave (QTc)> 480 ms on baseline ECG according to the Bazett formula. 7. Subjects with a history of one or more of the following cardiovascular disease in the last 6 months prior to the inclusion in the study: Angioplasty or stent placement Myocardial infarction Unstable Angina Coronary bypass surgery Symptomatic peripheral vascular disease Congestive heart failure Class II, III or IV New York Heart Association (NYHA) 8. Poorly controlled hypertension [defined as systolic blood pressure (SBP) = 140 mmHg or diastolic blood pressure stress (DBP) = 90 mmHg] while the patient is on antihypertensive therapy. Note: the commencement or adjustment of antihypertensive medication it is possible before the patient study start. In the baseline period measure blood pressure at least twice with a minimum interval of 24 hours. The mean values of SBP / DBP in each blood pressure reading should be <140/90 mmHg to include the subject in the study. 9. Background, in the last six months prior to the inclusion of stroke (including transient ischemic attacks), pulmonary embolism or deep vein thrombosis (DVT) untreated. Note: may be included subjects with recent DVT who received anticoagulants for at least 6 months. 10. Surgery or trauma in the last 28 days, or minor surgery (eg., Removal of central venous catheter) in the last 7 days prior to inclusion or unhealed wound, fracture, or ulcer. 11. Evidence of active bleeding or bleeding diathesis. 12. Hemoptysis within 6 weeks prior to inclusion. 13. Pregnant or breastfeeding. 14. Any medical condition (eg. Uncontrolled infection), psychiatric or other to be serious and / or unstable and may interfere with the safety of the patient, obtaining informed consent or compliance with study procedures.

Study Design


Intervention

Drug:
Pazopanib + interferon alpha 2A
Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days. Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient

Locations

Country Name City State
Spain Hospital Clínic Barcelona
Spain Hospital del Mar Barcelona
Spain Instituto Catalán de Oncología, Hospitalet del Llobregat Hospitalet de Llobregat Barcelona
Spain Hospital Clínico San Carlos Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Central de Asturias Oviedo
Spain Hospital Son Espases Palma
Spain Clinica Univ. Navarra Pamplona
Spain Centro Integral Oncológico Clara Campal Sanchinarro Sanchinarro - Madrid
Spain Hospital Virgen de la Macarena Sevilla
Spain Hospital Virgen del Rocio Sevilla
Spain Hospital Virgen de la Salud Toledo
Spain IVO Valencia

Sponsors (2)

Lead Sponsor Collaborator
Spanish Oncology Genito-Urinary Group GlaxoSmithKline

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) - Phase I The MTD is defined as the dose at wich two of the patients have experienced dose-limiting toxicity. Up to September 2012
Primary Efficacy, response rate (Phase II) Response rate is defined as the percentage of patients with complete response or partial response confirmed according RECIST v.1.1 Up to July 2013
Secondary Progression free survival Period between the start of treatment until the day in in wich the progression is confirmed by RECIST guidelines (version 1.1) or death from any cause. Up to July 2013
Secondary Overall Survival Period between the start of treatment and date of death from any cause. Up to December 2013
Secondary Frequency of adverse events Toxicity evaluation of the combination using the NCI-CTC Criteria version 3.0 Up to July 2013
Secondary Translational Substudy To analyze the different biomarkers and their variations with clinical outcomes of patients. Up to December 2013
See also
  Status Clinical Trial Phase
Recruiting NCT05361434 - A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
Recruiting NCT05928806 - Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial Phase 2
Recruiting NCT03647878 - Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Completed NCT00197860 - Dendritic Cell Based Therapy of Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT05444933 - A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.
Recruiting NCT05522231 - Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) Phase 2/Phase 3
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05641545 - IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients Phase 1
Active, not recruiting NCT02231749 - Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Phase 3
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Terminated NCT01582672 - Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma Phase 3
Completed NCT03200717 - Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment Phase 2
Active, not recruiting NCT05122546 - CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Phase 1
Completed NCT00853372 - AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib Phase 2
Active, not recruiting NCT02735252 - PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer N/A
Recruiting NCT05868174 - Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors Phase 1
Completed NCT00467025 - AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Phase 2
Active, not recruiting NCT03829111 - CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer Phase 1
Recruiting NCT05703854 - Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma Phase 1/Phase 2
Completed NCT01076010 - An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). Phase 3